Member Contact: Shane Duncan
Position: General Manager, Commercial
Industry: Biotech & Pharmaceuticals
Cann Group Limited (ASX:CAN) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group Limited was the first company in Australia to be granted a cannabis cultivation licence, and has subsequently been issued a manufacturing licence. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.
As one of the largest companies in the Australian medicinal cannabis sector, we are involved in the whole process of delivering medicinal cannabis to the Australian community, from plant to patient. As the Chairman of Medicinal Cannabis Industry Australia (MCIA), our CEO Peter Crock has an intimate working knowledge of the sector. Cann greatly appreciates its membership of the BioMelbourne Network due to the network’s involvement in agribiotech, research (both on plants and in patients), GMP manufacturing and regulatory issues surrounding medicinal cannabis.